Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/17246Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Peponi, E. | en |
| dc.contributor.author | Balta, S. | en |
| dc.contributor.author | Tasiou, I. | en |
| dc.contributor.author | Gogou, P. | en |
| dc.contributor.author | Capizzello, A. | en |
| dc.contributor.author | Pitouli, E. | en |
| dc.contributor.author | Tsekeris, P. | en |
| dc.date.accessioned | 2015-11-24T18:37:55Z | - |
| dc.date.available | 2015-11-24T18:37:55Z | - |
| dc.identifier.issn | 1107-0625 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/17246 | - |
| dc.rights | Default Licence | - |
| dc.subject | 3dcrt | en |
| dc.subject | head and neck cancer | en |
| dc.subject | recurrence | en |
| dc.subject | re-irradiation | en |
| dc.subject | squamous-cell carcinoma | en |
| dc.subject | 2nd primary head | en |
| dc.subject | prognostic-factors | en |
| dc.subject | concomitant chemoradiotherapy | en |
| dc.subject | concurrent chemotherapy | en |
| dc.subject | salvage reirradiation | en |
| dc.subject | locally recurrent | en |
| dc.subject | phase-i | en |
| dc.subject | cancer | en |
| dc.subject | radiotherapy | en |
| dc.title | Reirradiation for recurrent head and neck carcinoma | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000309793000009 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2012 | - |
| heal.abstract | Purpose: To present the outcome and toxicity profile of reirradiation (re-RT) in patients with recurrent head and neck cancer (HNC). Methods: From 1995 to 2009, 35 patients underwent re-RT at our institution. Twenty-seven (77%) patients were initially diagnosed with stage III/IV disease. The median total doses of irradiation first and second courses were 66.0 Gy (range 54.0-70.0) and 55.8 Gy (range 32.5-66.6), respectively The median time from the first course of irradiation to re-RT was 25.2 months (range 8-136). Six (17%) patients underwent salvage surgery before reirradiation. Concurrent chemotherapy was administered to 18(51%) patients. Results: With a median follow-up of 12.9 months (range 2.5-109.6), the 1- and 2-year locoregional control (LRC) rates were 41 and 9%, respectively. The 1- and 2-year disease free survival (DFS) rates were 30 and 7%, respectively. The 1- and 2-year overall survival (OS) rates were 42.9 and 7.9%, respectively. Grade 3 acute toxicity was reported in 7 (20%) patients while grade 3-4 late radiation-induced complications were seen in 8(23%) patients. In univariate analysis, an improvement in OS was observed in patients with initial N0/N1 stage vs. those with N2/N3 stage (p=0.004). Prior neoadjuvant chemotherapy was associated with significantly inferior OS (p=0.028), while neoadjuvant chemotherapy in recurrence was predictive of improved LRC (p=0.041). Conclusion: re-RT in HN cancer is associated with poor prognosis, especially in patients with inoperable disease. Complications due to treatment are not infrequent. Nonetheless, our outcomes remain encouraging and applicable to a carefully selected patient population. | en |
| heal.journalName | Journal of Buon | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
